ALK and non-small cell lung carcinoma: Actionable oncogenic driver mutations in NSCLC, such as epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement, rarely exist in pulmonary LELC (7).